Ohta Hiroaki
Tokyo Women's Medical University, Department of Obstetrics and Gynecology.
Clin Calcium. 2008 Oct;18(10):1442-50.
Several lines of evidence demonstrate that the objective of osteoporosis treatment consists in the prophylaxis of osteoporotic fractures. With the endpoint of osteoporosis treatment thus clarified, currently, the selective estrogen receptor modulator (SERM) raloxifine represents the mainstay of therapy for osteoporosis, together with the antiresorptive agents bisphosphonates. Thus, this review has drawn mainly on the results of the MORE study to explore the efficacy of raloxifene in inhibiting bone metabolism, increasing bone mineral density effects, and preventing bone fractures. Notably, the available evidence for raloxifene suggests that the efficacy of raloxifene in preventing bone fractures has not only to do with bone mineral density but also to do with bone quality.
多项证据表明，骨质疏松症治疗的目标在于预防骨质疏松性骨折。随着骨质疏松症治疗的终点得以明确，目前，选择性雌激素受体调节剂（SERM）雷洛昔芬与抗吸收药物双膦酸盐一起，成为骨质疏松症治疗的主要手段。因此，本综述主要借鉴了MORE研究的结果，以探讨雷洛昔芬在抑制骨代谢、增加骨矿物质密度以及预防骨折方面的疗效。值得注意的是，现有关于雷洛昔芬的证据表明，雷洛昔芬预防骨折的疗效不仅与骨矿物质密度有关，还与骨质量有关。
